Aquestive Therapeutics (NASDAQ:AQST) Raised to Strong-Buy at BidaskClub

Aquestive Therapeutics (NASDAQ:AQST) was upgraded by investment analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a report issued on Tuesday, BidAskClub reports.

A number of other analysts also recently weighed in on the stock. Royal Bank of Canada reaffirmed a “buy” rating and issued a $8.00 target price on shares of Aquestive Therapeutics in a research report on Thursday, August 6th. Zacks Investment Research cut shares of Aquestive Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, June 3rd. Wedbush restated a “buy” rating and set a $33.00 target price on shares of Aquestive Therapeutics in a research note on Wednesday, September 2nd. ValuEngine cut shares of Aquestive Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, September 11th. Finally, HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Aquestive Therapeutics in a research note on Tuesday, June 30th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $15.00.

Shares of Aquestive Therapeutics stock opened at $7.82 on Tuesday. The company’s fifty day simple moving average is $7.24 and its two-hundred day simple moving average is $4.93. The company has a market cap of $262.91 million, a P/E ratio of -4.39 and a beta of 3.73. Aquestive Therapeutics has a 12-month low of $1.41 and a 12-month high of $10.00.

Aquestive Therapeutics (NASDAQ:AQST) last released its earnings results on Tuesday, August 4th. The company reported ($0.07) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.36. The business had revenue of $21.68 million during the quarter, compared to analysts’ expectations of $9.14 million. As a group, sell-side analysts expect that Aquestive Therapeutics will post -1.55 EPS for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new stake in shares of Aquestive Therapeutics in the 2nd quarter valued at about $53,000. Jane Street Group LLC purchased a new stake in Aquestive Therapeutics during the 2nd quarter worth approximately $54,000. American International Group Inc. acquired a new position in Aquestive Therapeutics during the 2nd quarter valued at approximately $59,000. State Board of Administration of Florida Retirement System purchased a new position in shares of Aquestive Therapeutics in the second quarter worth $62,000. Finally, Two Sigma Advisers LP lifted its stake in shares of Aquestive Therapeutics by 57.3% during the first quarter. Two Sigma Advisers LP now owns 17,300 shares of the company’s stock worth $38,000 after buying an additional 6,300 shares during the period. 55.10% of the stock is owned by institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally.

Further Reading: Accumulation/Distribution

Analyst Recommendations for Aquestive Therapeutics (NASDAQ:AQST)

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.